We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00093080
Recruitment Status : Completed
First Posted : October 4, 2004
Last Update Posted : February 13, 2015
Ariad Pharmaceuticals
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Brief Summary:
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.

Condition or disease Intervention/treatment Phase
Leiomyosarcoma Liposarcoma Osteosarcoma Sarcoma, Soft Tissue Metastases Drug: ridaforolimus Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 216 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma
Study Start Date : October 2004
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Arm Intervention/treatment
Experimental: Ridaforolimus
12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
Drug: ridaforolimus
12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
Other Names:
  • deforolimus (until May 2009)
  • AP23573
  • MK-8669

Primary Outcome Measures :
  1. Number of participants with Clinical Benefit Response (CBR) Using Response Criteria in Solid Tumors (RECIST) [ Time Frame: Day 1 up to 4 years or discontinuation from study ]

Secondary Outcome Measures :
  1. Time to Tumor Progression [ Time Frame: Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) ]
  2. Progression Free Survival [ Time Frame: Day 1 to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) ]
  3. Overall Survival [ Time Frame: Day 1 to the date of death, or the date of last contact (up to 4 years) ]
  4. Duration of Response [ Time Frame: Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years) ]
  5. Number of participants experiencing adverse events [ Time Frame: From first dose up to 30 days after last dose (up to 1 year) ]
  6. Number of participants who discontinued study drug due to adverse events [ Time Frame: From first dose up to the last dose (up to 1 year) ]
  7. Mean ridaforolimus blood levels within 5 minutes post intravenous infusion [ Time Frame: Day 1 and Day 5 of Cycle 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients ≥15 years of age with metastatic and/or unresectable sarcomas of the following histological subgroups: Bone sarcomas, such as osteosarcoma and Ewings sarcoma; Leiomyosarcoma; Liposarcomas; Any other soft tissue sarcoma except gastrointestinal stromal tumors (GIST). Patients with well-differentiated liposarcoma or desmoid tumors must have demonstrated progressive disease within the previous 6 months
  • Presence of at least one measurable lesion that: Can be accurately measured in at least one dimension with longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral computerized tomography (CT) scan (or otherwise at least twice the reconstruction interval for CT or magnetic resonance imaging [MRI] scans)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • Minimum life expectancy of 3 months
  • Adequate renal and hepatic function, as specified in the protocol
  • Adequate bone marrow function, as specified in the protocol
  • Serum cholesterol <350 mg/dL and triglycerides < 400 mg/dL
  • Male and female patients who are not surgically sterile or postmenopausal must agree to use reliable methods of birth control for the duration of the study until 30 days after the last dose of study drug
  • Able to understand and give written informed consent

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Presence of brain metastases
  • Prior therapy with rapamycin, rapamycin analogues or tacrolimus
  • Prior anticancer treatment (chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of ridaforolimus
  • Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of ≤ grade 1 by National Cancer Institute (NCI) toxicity criteria)
  • Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)
  • Known or suspected hypersensitivity to drugs formulated with polysorbate 80 (Tween) or any other excipient contained in the study drug
  • Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)
  • Significant uncontrolled cardiovascular disease
  • Active infection requiring systemic therapy
  • Known human immunodeficiency virus (HIV) infection
  • Treatment with any investigational agent within 4 weeks prior to the first dose of ridaforolimus
  • Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for 2 weeks prior to first planned dose of study drug
  • Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of ridaforolimus
  • Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug
Publications of Results:
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier: NCT00093080    
Other Study ID Numbers: 8669-018
AP23573-04-202 ( Other Identifier: Ariad Pharmaceuticals, Inc. )
2004-002231-92 ( EudraCT Number )
First Posted: October 4, 2004    Key Record Dates
Last Update Posted: February 13, 2015
Last Verified: February 2015
Keywords provided by Merck Sharp & Dohme LLC:
Metastatic and/or unresectable soft tissue or
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Muscle Tissue
Neoplasms, Adipose Tissue